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© 2013 The Japan Society of Histochemistry andPodoplanin is a mucin-type glycoprotein which was first identified in podocytes. Recently,
podoplanin has been successively reported as a marker for brain and peripheral nerve
tumors, however, the distribution of podoplanin-expressing cells in normal nerves has not
been fully investigated. This study aims to examine the podoplanin-expressing cell distribution
in the mouse head and nervous systems. An immunohistochemical study showed that the
podoplanin-positive areas in the mouse peripheral nerve and spinal cord are perineurial
fibroblasts, satellite cells in the dorsal root ganglion, glia cells in the ventral and dorsal horns,
and schwann cells in the ventral and dorsal roots; in the cranial meninges the dura mater,
arachnoid, and pia mater; in the eye the optic nerve, retinal pigment epithelium, chorioidea,
sclera, iris, lens epithelium, corneal epithelium, and conjunctival epithelium. In the mouse
brain choroid plexus and ependyma were podoplanin-positive, and there were podoplanin-
expressing brain parenchymal cells in the nuclei and cortex. The podoplanin-expressing cells
were astrocyte marker GFAP-positive and there were no differences in the double positive
cell distribution of several portions in the brain parenchyma except for the fornix. The results
suggest that podoplanin may play a common role in nervous system support cells and eye
constituents.
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I. Introduction
Podoplanin, also termed Aggrus/gp36/E11 antigen, is
a 38-kDa (mouse) or 36-kDa (human) mucin-type glyco-
protein with a high content of sialic acid [12, 13] which
was first identified in kidney glomerular epithelial cells,
podocytes [3, 26]. The Ebp1 is the only transcriptional
factor which has been reported to promote tumorigenesis by
the activation of the podoplanin gene [18]. In gliomas,
increases in podoplanin are caused by loss of PTEN and
activation of the PI3K-AKT-AP-1 signaling pathway,
accompanied by epigenetic regulation of PDPN promoter
activity. Silencing of the PDPN expression leads to reduced
proliferation and migration of glioma cells [21]. Therefore,
podoplanin has been considered as a candidate for target
protein in brain cancer treatment.
Podoplanin is commonly known as a useful marker
for lymphatic endothelium and type I alveolar epithelium
[22, 24, 32]. Podoplanin is also expressed in osteocytes
and osteoblasts [31], choroid plexus [11], perineurium
[20], mesothelial cells [4, 14], epidermal basal layer
cells [24], tooth germ epithelial cells, salivary gland myo-
epithelium [1, 6–8, 20, 23], thymus type I epithelial
cells, prostate myofibroblasts, follicular dendritic cells, and
immature cells such as fetal germ cells and developing
Sertoli cells [16, 25, 29, 33]. In nervous system tumors,
expression of podoplanin in schwannomas, ependymal
tumors, choroid plexus papillomas, meningiomas, astrocytic
tumors, medulloblastomas, and hemangioblastomas have
been reported [9, 10, 19, 27]. Therefore, it is thought
that glia cells commonly express podoplanin, however,
the distribution of podoplanin-positive cells in the nervous
system has not been fully investigated. This study aims
to examine the expression of podoplanin in the nervous
system.
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II. Materials and Methods
Animals
Closed line ICR mice (Japan Clea Inc., Osaka, Japan)
of gestational day 7 were purchased and one week-old
male mice (n=10) were used. Breeding and experiences
were performed in a room with 100% controlled atmo-
sphere which had passed an examination for bacteria in
the Fukuoka Dental College Animal Center. Mice grew
normally and lived healthily under conventional atmosphere
conditions with normal feeding in cages and rooms in
which lighting and temperature (22°C) were completely
controlled. The collection of the tissue was conducted
after euthanasia by 2% (1 l/min) isoflurane inhalation
with an anaesthetic apparatus and cervical dislocation. The
protocol for the animal use was reviewed and approved
by the animal experiment committee of Fukuoka Dental
College in accordance with the principles of the Helsinki
Declaration.
Immunohistochemistry
Tissue was fixed in 100% methanol for 10 min at
–20°C, and then immersed in 30% sucrose-PBS for 12 hr
at 4°C before freezing. Frozen 10 μm sections were cut in
a cryostat and fixed in 100% methanol for 5 min at –20°C.
To make paraffin-embedded sections, perfusion fixation
was performed through the heart with 500 ml of fixative
solution containing 4% formaldehyde-PBS after the eutha-
nasia described above. The dissected tissue was additionally
fixed by immersion in a 10% formalin-PBS solution for 8
hr at room temperature as fixing of the tissue for longer than
24 hr leads to masking or destruction of the podoplanin
antigen. The 5-μm thick paraffin-embedded sections were
cut using a rotary microtome, mounted on 3-aminopropyl-
triethoxysilane-coated slides, deparaffinized in changes of
xylene, rehydrated in decreasing concentrations of ethanol,
and rinsed with deionized distilled water for 10 min. Slides
were immersed in 10 mM sodium citrate buffer (pH 6.0)
and boiled in a microwave oven for 10 min to break
formalin-formed protein cross-links masking the podo-
planin antigen. After the boiling, the sections were rinsed
by 10 mM PBS and blocked with 0.1% goat serum. The
immunostaining was performed using the first and second
antibodies diluted into the blocking solution. All procedures
were performed after washing with 10 mM PBS for 30 min
at room temperature. Sections were exposed by primary
antibodies: 1 μg/ml of monoclonal hamster anti-mouse
podoplanin (AngioBio Co., Del Mar, CA) and 1 μg/ml of
polyclonal rabbit anti-mouse glial fibrillary acidic protein
(GFAP, Abcam plc., Cambridge, UK), for 8 hr at 4°C. After
the treatment with primary antibodies the sections were
washed three times in PBS for 10 min and immunostained
for 0.5 hr at 20°C with 0.1 μg/ml of second antibodies:
Alexa Fluor (AF) 488 or 568-conjugated goat anti-hamster
and goat anti-rabbit IgGs (Probes Invitrogen Com., Eugene,
OR). The immunostained sections were mounted in 50%
polyvinylpyrrolidone solution and examined by fluores-
cence microscopy (BZ-8100, Keyence Corp., Osaka, Japan)
or laser-scanning microscopy (LSM710, Carl Zeiss, Jena,
Germany) with a ×63 oil planapochromatic objective lens
(numerical aperture ×1.3).
Reverse transcription (RT)-PCR and real-time PCR
The brain tissue was peeled away from the cerebrum
within a 2 mm square by an 18-gauge needle under a
stereoscopic microscope. Total RNA extraction from tissue
of the cerebral cortex, hippocampus, thalamus, caudate
nucleus, and corpus callosum was performed with a
QIAshredder column and RNeasy kit (Qiagen, Inc., Tokyo,
Japan). Contaminating genomic DNA was removed using
DNAfree (Ambion, Huntingdon, UK), and the RT was
performed on 30 ng of total RNA, followed by 30 cycles
of PCR for amplification using the Ex Taq hot start version
(Takara Bio Inc., Otsu, Japan) with 50 pM of primer sets:
mouse β-actin (forward, 5'-GTTCTACAAATGTGGCTG
AGGA; reverse, 5'-ATTGGTCTCAAGTCAGTGTACAG,
411 bp), mouse podoplanin coding sequence region (for-
ward, 5'-CACCTCAGCAACCTCAGAC; reverse, 5'-AA
GACGCCAACTATGATTCCAA, 192 bp), where the
specificities had been confirmed by the manufacturer
(Sigma-Genosys Ltd., Cambridge, UK). The RT-PCR prod-
ucts were separated on 2% agarose gel (NuSieve; FMC,
Rockland, ME, USA) and visualized by Syber Green
(Takara). The correct size of the amplified PCR products
was confirmed by gel electrophoresis and amplification
of accurate targets was confirmed by sequence analysis. To
quantify podoplanin mRNA generation, cDNA samples were
analyzed by real-time quantitative PCR. A total of 1 μl of
cDNA was amplified in a 25-μl volume of PowerSYBR
Green PCR Master Mix (Applied Biosystems, Foster City,
CA, USA) in a Stratagene Mx3000P real-time PCR system
(Agilent Technologies, Inc., Santa Clara, CA, USA), and
the fluorescence was monitored at each cycle. Cycle param-
eters were 95°C for 15 min to activate Taq followed by 35
cycles of 95°C for 15 s, 58°C for 1 min, and 72°C for 1
min. For the real-time analysis, two standard curves were
constructed from amplicons for both the β-actin and target
genes (podoplanin) in three serial 4-fold dilutions of cDNA.
The β-actin or target gene cDNA levels in each sample were
quantified against β-actin or the target gene standard curves
by allowing the Mx3000P software to accurately determine
each cDNA unit. Finally, target gene cDNA units in each
sample were normalized to β-actin cDNA units. Thus,
the relative target gene expression units were expressed
as arbitrary units, calculated according to the following
formula: relative target gene expression units=target gene
cDNA units/β-actin cDNA units.
Measurement of the number of podoplanin and GFAP 
positive cells
The numbers of podoplanin and GFAP double positive
glial cells were determined by counting at five different
areas (75 μm×75 μm). All experiments were repeated five
times, and the data are expressed as means±standard devi-
Podoplanin Expression in Nervous Systems 173
ations (SD). Statistically significant differences (p<0.05)
were determined by the unpaired two-tailed Student’s t
test with STATVIEW 4.51 software (Abacus concepts,
Calabasas, CA).
Measurements of the areas of podoplanin expressing cells
The areas of podoplanin-positive glial cells were
measured at ten different spots (0.36 mm×0.36 mm) in the
mouse brain section images at 100× magnification using
ImageJ (National Institutes of Health, Bethesda, MD). All
experiments were repeated five times, and data are
expressed as means±SD. Statistically significant differences
(p<0.05) were determined by the unpaired two-tailed
Student’s t test with STATVIEW 4.51 software (Abacus).
Statistics
Real-time PCR analysis was repeated five times and
the data was expressed as mean±SD. The statistical sig-
nificance of differences (p<0.05) was determined by the
Student’s t test and one-way ANOVA with STATVIEW
4.51 software (Abacus concepts, Calabasas, CA, USA).
III. Results
The immunohistochemical examination of the mouse
tongue showed that the lingual muscle and blood vessels
are podoplanin-negative but that the lymphatic vessels
and perineurium around the lingual nerve are podoplanin-
positive (Fig. 1). The immunohistochemical examination of
the cranial bone showed that the periosteum, osteocytes,
dura mater, arachnoid, and pia mater are also podoplanin-
positive (Fig. 1). The immunohistochemical examination on
the mouse spinal cord showed that the meninges, satellite
cells in the dorsal root ganglion, periosteum of vertebra, glia
cells around ventral horn, and schwann cells in the ventral
and dorsal roots are podoplanin-positive (Fig. 2). The
immunohistochemical study of the mouse eye showed that
the optic nerve, pigment epithelium, retina near the disk,
chorioidea, sclera, iris, lens epithelium, corneal epithe-
lium, and conjunctival epithelium are podoplanin-positive
(Fig. 3). For the mouse brain the immunohistochemical
study showed that the choroid plexus and ependymal cells
are podoplanin-positive, and that in the brain parenchyma
there are cells expressing both podoplanin and the astrocyte
marker GFAP in the cerebral cortex, hippocampus, thala-
Fig. 1. Podoplanin expression in mouse lymphatic vessels, bone, and connective tissue. The immunostained sections were re-stained by H-E
staining. In the mouse tongue, the lingual muscle and blood vessels (arrows in HE) are podoplanin-negative but lymphatic vessels (arrows
in immunostaining) and the perineurium around the lingual nerve (arrowheads) are podoplanin-positive. In the cranium, podoplanin-positive
areas (arrowheads) are observed in periosteum (Pe), dura mater (DM), and pia mater (PM). Osteocytes in the cranial bone are also podoplanin-
positive (arrows). Bar=100 μm.
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Fig. 2. Immunostaining for podoplanin in a horizontal section of mouse spinal cord. The immunostained sections were re-stained by H-E
staining. The regions which are highlighted by boxes in the top right podoplanin immunostaining panel correspond to the lower panels with
laser-scanning microscopic images (a–d). In the spinal cord, the podoplanin-positive areas are observed in (a) meninges, (b) satellite cells of
the dorsal root ganglion (DG), (c) periosteum of the vertebra, and (d) glia cells of the ventral horn (VH). Schwann cells in the ventral root
(VR) and in the dorsal root (DR) are also podoplanin-positive. Bar=100 μm (upper), 20 μm (lower).
Fig. 3. Immunostaining for podoplanin in a horizontal section of the mouse eye. The immunostained sections were re-stained by H-E staining.
The regions which are highlighted by boxes in the upper figure of podoplanin immunostaining correspond to the lower figures of laser-scanning
microscopic images (a–d). The podoplanin-positive areas are the optic nerve (ON), pigment epithelium (PE), retina (Re) near the optic disk,
chorioidea (Ch), sclera (Sc), lens epithelium (LE), corneal epithelium (CoE), and conjunctival epithelium (CjE). Bar=100 μm.
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mus, and fornix (Fig. 4). In the quantitative analysis for the
podoplanin and GFAP double positive cells in the mouse
brain, there were no differences in areas and numbers of
double positive cells in the cerebral cortex, hippocampus,
thalamus, and caudate nucleus (Fig. 5). These areas and cell
numbers were statistically significantly larger than the num-
bers in the fornix. In the analysis for the gene expression
of podoplanin in the mouse brain, there were no differences
in the mRNA amounts in the cerebral cortex, hippocampus,
thalamus, and caudate nucleus but these mRNA amounts
were statistically significantly larger than those in the fornix
(Fig. 6).
IV. Discussion
The study used anti-podoplanin where the specificity
has been confirmed in our previous studies [30], and
showed that the reaction products were observed in lym-
phatic vessels but not in blood vessels as also reported
elsewhere, showing that the immunohistochemistry for
podoplanin was successful (Fig. 1). The immunohisto-
chemical examination on the cranial and vertebra bone
showed that osteocytes, periosteal cells, and dura mater
fibroblasts were podoplanin-positive (Figs. 1, 2). It is
thought that the cranial and vertebra bone-related mesen-
chymal cells have the ability to produce podoplanin [31].
In the peripheral nerve tumors, it has been reported that
podoplanin expresses in 76–100% of schwannomas and in
21% of spindle malignant peripheral nerve sheath tumors
[10]. The study here showed that perineurial fibroblasts of
peripheral nerves, satellite cells in the ganglion, glia cells
and schwann cells in the spinal cord and nerve roots, are
generally podoplanin-positive (Figs. 1, 2). This suggests
that cells supporting nerves like glia cells have the ability
to express podoplanin. It has recently been reported that the
expression of podoplanin is a characteristic of meningiomas
which arise from arachnoid mater covering the surface of
the brain and spinal cord [28]. The study here showed that
meningeal fibroblasts and glial cells express podoplanin
(Figs. 1, 2), suggesting that the expression of podoplanin is
a common characteristic among cells supporting meninges.
In the mouse eye podoplanin expression was observed in
Fig. 4. Immunostaining for podoplanin in a horizontal section of the mouse brain. The immunostained sections were re-stained by H-E staining.
There are cells expressing both podoplanin and GFAP (arrowheads) in the cerebral cortex (Ctx), hippocampus (Hi), thalamus (Th), and fornix
(Fo). Pia mater (PM), choroid plexus (CP), and ependymal cells in the lateral ventricle are also podoplanin- and GFAP-double positive
(arrows). Bar=100 μm.
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epithelial cells including pigment, lens, cornea, iris, and
conjunctiva, and also in fibroblasts of the chorioidea
(Fig. 3), suggesting that the expression of podoplanin is a
common characteristic of the epithelial and endothelial cells
which form the eyes.
There have been reports that podoplanin is expressed
in 25.6% of anaplastic astrocytomas and in 47.0% of
glioblastomas, and that podoplanin mRNA and protein
expression are markedly higher in glioblastomas than in
anaplastic astrocytomas [19]. The podoplanin expression
may be seen as a useful index of the malignancy of glioma
[12, 13, 27], however, this study showed that there are
podoplanin-positive cells in the choroid plexus and ependy-
mal cells as also reported previously [11], and further, that
in the mouse brain parenchyma there are cells expressing
podoplanin and GFAP which is an intermediate filament
specific for astrocytes (Fig. 4). There were no differences
in the podoplanin and GFAP double positive cell distribu-
tions of the several portions in the brain parenchyma except
in the fornix (Figs. 5, 6), suggesting that the expression of
podoplanin is a characteristic of astrocytes.
It has been reported that a biological role of podo-
planin is the rearrangement of the actin cytoskeleton and
dependent on the binding activity with a cytoplasmic linker
protein ezrin. Podoplanin up-regulates a Rho-GTPase activ-
ity resulting in ezrin phosphorylation [17, 26, 34]. Phospho-
rylated ezrin mediates the connection between membrane
proteins and F-actin, and an increase in podoplanin at the
cell membrane promotes the formation of membrane-actin
structures critical for the cell shape and also induces plasma
membrane extensions based on the cytoskeleton rearrange-
ment [2, 5, 15, 27]. Podoplanin may contribute to form the
cytoskeleton of the peripheral and central nervous system
support cells, and of eye constituents.
Fig. 5. Quantitative analysis of podoplanin-positive cells in the mouse brain. (A) Area of podoplanin and GFAP double positive cells in the
cerebral cortex (Ctx), hippocampus (Hi), thalamus (Th), caudate nucleus (CN), and fornix (Fo). The areas of podoplanin-positive cells in the
fornix were statistically significantly smaller than other areas. There were no differences in the tested areas except for the fornix. Data are
expressed as means±SD. *Significantly different (p<0.01). (B) Number of podoplanin and GFAP double positive cells in the cerebral cortex
(Ctx), hippocampus (Hi), thalamus (Th), caudate nucleus (CN), and fornix (Fo). Average of the number of cells in five spots (75 μm2×75 μm2)
in the fornix were statistically significantly fewer than in other areas. There were no differences in the tested areas except for in the fornix.
Data are expressed as means±SD. *Significantly different (p<0.01).
Fig. 6. Gene analysis for the expression of podoplanin mRNA in the
mouse brain. Total RNA extraction from tissue of the cerebral
cortex (Ctx), hippocampus (Hi), thalamus (Th), caudate nucleus
(CN), and fornix (Fo) were examined. (A) Real-time PCR analysis.
Relative mRNA amounts are expressed in arbitrary units. Target
gene cDNA units in each sample were normalized to β-actin cDNA
units. The podoplanin mRNA amount in the fornix was signifi-
cantly smaller than in other areas. There were no differences in the
tested areas except for in the fornix. *Significantly different
(p<0.01). (B) RT-PCR analysis. The intensity of amplicon for
podoplanin mRNA was significantly lower in the fornix than in
other areas. There were no differences in the tested areas except for
in the fornix. The intensity of amplicon for β-actin mRNA was
similar among all areas.
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